Phase 3 trial team-ET in 106 high-risk Essential Thrombocythemia patients, demonstrating non-inferiority of anathromb, a novel, extended-release anagrelide formulation, to the licensed comparator
2016
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI